| Previous Close | 1.380 |
| Open | 1.380 |
| Bid | 1.370 x 100 |
| Ask | 1.380 x 900 |
| Day's Range | 1.360 - 1.390 |
| 52 Week Range | 1.260 - 4.250 |
| Volume | 117,976 |
| Avg. Volume | 759,203 |
| Market Cap | 53.92M |
| Beta | -1.69 |
| PE Ratio (TTM) | -2.50 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- American City Business Journals•28 days ago
Watertown’s pSivida files for European approval of treatment to prevent blindness
After unveiling positive data last week from a late-stage trial of its experimental, long-acting treatment for a leading cause of blindness, Watertown-based pSivida said Thursday that it has filed for approval in Europe. The 21-employee company (PSDV) said it had submitted an application to market its product, Durasert, in the European Union. It’s a major milestone for pSivida following a turbulent 2016 in which the company’s stock price fell precipitously and it got a new CEO.
- Thomson Reuters StreetEvents•last month
Edited Transcript of PSDV earnings conference call or presentation 4-May-17 8:30pm GMT
Q3 2017 pSivida Corp Earnings Call
- Capital Cube•2 months ago
ETFs with exposure to pSivida Corp. : May 22, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to pSivida Corp. Here are 5 ETFs with the largest exposure to PSDV-US. Comparing the performance and risk of pSivida Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
